Infection and injury cause controlled immune and inflammatory responses involving complex molecular signalling networks that lead to the production of bioactive lipid mediators.
Eicosanoids are bioactive lipid mediators derived from oxygenated polyunsaturated fatty acids.
Similar to cytokine signalling and inflammasome formation, eicosanoid signalling has been viewed primarily as a pro-inflammatory component of innate immunity.
Recent advances in lipidomics technologies have helped to elucidate unique eicosanoids and related docosanoids with anti-inflammatory and pro-resolution functions that are a key component of the inflammatory response.
Receptor activation initiated by Toll-like receptors (TLRs), purinergic receptors and other signalling pathways induced by infectious agents generates both pro-inflammatory and anti-inflammatory metabolites resulting in an eicosanoid storm.
Lipidomics has advanced our overall understanding of the inflammatory response and its therapeutic implications, and has suggested new pharmacological approaches.
Controlled immune responses to infection and injury involve complex molecular signalling networks with coordinated and often opposing actions. Eicosanoids and related bioactive lipid mediators derived from polyunsaturated fatty acids constitute a major bioactive lipid network that is among the most complex and challenging pathways to map in a physiological context. Eicosanoid signalling, similar to cytokine signalling and inflammasome formation, has primarily been viewed as a pro-inflammatory component of the innate immune response; however, recent advances in lipidomics have helped to elucidate unique eicosanoids and related docosanoids with anti-inflammatory and pro-resolution functions. This has advanced our overall understanding of the inflammatory response and its therapeutic implications. The induction of a pro-inflammatory and anti-inflammatory eicosanoid storm through the activation of inflammatory receptors by infectious agents is reviewed here.
Your institute does not have access to this article
Open Access articles citing this article.
Nature Communications Open Access 27 June 2022
The FADS1 genotypes modify the effect of linoleic acid-enriched diet on adipose tissue inflammation via pro-inflammatory eicosanoid metabolism
European Journal of Nutrition Open Access 14 June 2022
Bioactive lipid screening during respiratory tract infections with bacterial and viral pathogens in mice
Metabolomics Open Access 10 June 2022
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871–1875 (2001).
Buczynski, M. W., Dumlao, D. S. & Dennis, E. A. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 50, 1015–1038 (2009). A paper that describes and compares the genes and enzymes responsible for the formation of major and minor eicosanoids and related lipid mediators from arachidonic acid and related PUFAs in humans, mice and rats.
Gross, O., Thomas, C. J., Guarda, G. & Tschopp, J. The inflammasome: an integrated view. Immunol. Rev. 243, 136–151 (2011).
Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397–411 (2013).
Norris, P. C., Gosselin, D., Reichart, D., Glass, C. K. & Dennis, E. A. Phospholipase A2 regulates eicosanoid class switching during inflammasome activation. Proc. Natl Acad. Sci. USA 111, 12746–12751 (2014). A study demonstrating macrophage reprogramming from pro-inflammatory to pro-resolution mediator synthesis that parallels classic inflammasome activation: a link between inflammation and resolution, as well as between eicosanoid and cytokine storms.
Harkewicz, R. & Dennis, E. A. Applications of mass spectrometry to lipids and membranes. Annu. Rev. Biochem. 80, 301–325 (2011).
Dumlao, D. S., Buczynski, M. W., Norris, P. C., Harkewicz, R. & Dennis, E. A. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta 1811, 724–736 (2011).
Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014). A definitive review of inflammation resolution and the biosynthesis, receptor signalling and biological roles of the lipid mediators involved.
Quehenberger, O. & Dennis, E. A. The human plasma lipidome. New Engl. J. Med. 365, 1812–1823 (2011). A comprehensive analysis and survey of the diversity of lipid species in plasma and their roles as participants in and biomarkers for a wide range of human diseases.
Wada, M. et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 282, 22254–22266 (2007).
Nebert, D. W. & Dalton, T. P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 6, 947–960 (2006).
Brash, A. R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274, 23679–23682 (1999).
Sala, A., Folco, G. & Murphy, R. C. Transcellular biosynthesis of eicosanoids. Pharmacol. Rep. 62, 503–510 (2010).
Ueno, N., Takegoshi, Y., Kamei, D., Kudo, I. & Murakami, M. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem. Biophys. Res. Commun. 338, 70–76 (2005).
Newcomer, M. E. & Gilbert, N. C. Location, location, location: compartmentalization of early events in leukotriene biosynthesis. J. Biol. Chem. 285, 25109–25114 (2010).
Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V. & Kokotos, G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 111, 6130–6185 (2011). A complete review of the PLA2 superfamily of enzymes that initiate the release of arachidonic acid for eicosanoid formation, including a discussion of their biological roles and related therapeutic intervention strategies.
Vane, J. R. Biomedicine. Back to an aspirin a day? Science 296, 474–475 (2002).
Rajakariar, R., Yaqoob, M. M. & Gilroy, D. W. COX-2 in inflammation and resolution. Mol. Interv. 6, 199–207 (2006).
Chen, C. COX-2's new role in inflammation. Nat. Chem. Biol. 6, 401–402 (2010).
Norris, P. C. & Dennis, E. A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl Acad. Sci. USA 109, 8517–8522 (2012). A study that confirms the biochemical mechanism of actions of ω- 3 PUFAs on COX1 and COX2 that relate to cardiovascular complications of NSAIDs; a role for PUFA elongation and desaturation is also identified.
Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145–182 (2000).
Kühn, H. & O'Donnell, V. B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res. 45, 334–356 (2006).
Norris, P. C., Reichart, D., Dumlao, D. S., Glass, C. K. & Dennis, E. A. Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype. J. Leukocyte Biol. 90, 563–574 (2011).
Lawrence, T., Willoughby, D. A. & Gilroy, D. W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2, 787–795 (2002).
Shinomiya, S. et al. Regulation of TNFα and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. 61, 1153–1160 (2001).
Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568–575 (1983).
Lammermann, T. et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 498, 371–375 (2013). The definitive study on LTB 4 that demonstrates its ability to markedly enhance neutrophil recruitment to sites of tissue damage.
Murakami, K., Ide, T., Suzuki, M., Mochizuki, T. & Kadowaki, T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor α. Biochem. Biophys. Res. Commun. 260, 609–613 (1999).
Huang, J. T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378–382 (1999).
Roman, R. J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131–185 (2002).
von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490, 107–111 (2012). An important demonstration of the life-threatening role that eicosanoids produced by COX1 have in toxic shock, which does not depend on cytokine storms.
Bitto, A. et al. Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. Crit. Care 16, R32 (2012).
Balsinde, J., Balboa, M. A. & Dennis, E. A. Antisense inhibition of group VI Ca2+-independent phospholipase A2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. J. Biol. Chem. 272, 29317–29321 (1997).
Fitzpatrick, F. A. & Soberman, R. Regulated formation of eicosanoids. J. Clin. Invest. 107, 1347–1351 (2001).
Buczynski, M. W. et al. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. J. Biol. Chem. 282, 22834–22847 (2007).
Naraba, H. et al. Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. J. Immunol. 160, 2974–2982 (1998).
Brock, T. G., McNish, R. W. & Peters-Golden, M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2 . J. Biol. Chem. 274, 11660–11666 (1999).
Mandal, A. K. et al. The nuclear membrane organization of leukotriene synthesis. Proc. Natl Acad. Sci. USA 105, 20434–20439 (2008).
Kihara, Y. et al. Modeling of eicosanoid fluxes reveals functional coupling between cyclooxygenases and terminal synthases. Biophys. J. 106, 966–975 (2014). An integrated experimental and computational confirmation of the functional coupling mechanisms for the biosynthesis of prostaglandins and thromboxane by COX1, COX2 and downstream enzymes, including the flux of metabolites over time during inflammation.
Folco, G. & Murphy, R. C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58, 375–388 (2006).
Chiang, N., Arita, M. & Serhan, C. N. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids 73, 163–177 (2005).
Claria, J. & Serhan, C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl Acad. Sci. USA 92, 9475–9479 (1995).
Morris, T. et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089–2096 (2009).
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–619 (2001).
Chan, M. M. & Moore, A. R. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184, 6418–6426 (2010).
Gasser, O. & Schifferli, J. A. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood 104, 2543–2548 (2004).
Dalli, J. & Serhan, C. N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60–e72 (2012).
Miki, Y. et al. Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J. Exp. Med. 210, 1217–1234 (2013).
Dioszeghy, V. et al. 12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J. Immunol. 181, 6514–6524 (2008).
Li, P. et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 155, 200–214 (2013).
Harmon, G. S. et al. Pharmacological correction of a defect in PPAR-γ signaling ameliorates disease severity in Cftr-deficient mice. Nat. Med. 16, 313–318 (2010).
Mayer-Barber, K. D. & Sher, A. Cytokine and lipid mediator networks in tuberculosis. Immunol. Rev. 264, 264–275 (2015).
Tobin, D. M. et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717–730 (2010).
Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014).
Coulombe, F. et al. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 40, 554–568 (2014).
Blaho, V. A., Buczynski, M. W., Brown, C. R. & Dennis, E. A. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J. Biol. Chem. 284, 21599–21612 (2009).
Blaho, V. A., Zhang, Y., Hughes-Hanks, J. M. & Brown, C. R. 5-lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis. J. Immunol. 186, 3076–3084 (2011).
Blaho, V. A., Mitchell, W. J. & Brown, C. R. Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease. Arthritis Rheumatism 58, 1485–1495 (2008).
Maier, N. K., Leppla, S. H. & Moayeri, M. The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J. Immunol. 194, 2776–2785 (2015).
Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012). An example of lipid mediator signalling that guards against antibiotic resistance.
Morita, M. et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153, 112–125 (2013). An extensive study that links a defect in pro-resolving mediator synthesis to compromised immunity to influenza virus.
Tam, V. C. et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 154, 213–227 (2013). A report of comprehensive transcriptomics, proteomics and lipidomics carried out during mouse influenza virus infection that identified distinct lipid biomarkers during active infection that are also observed in human influenza virus infections.
Ramon, S. et al. The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? J. Immunol. 193, 6031–6040 (2014).
Aharony, D. Pharmacology of leukotriene receptor antagonists. Am. J. Respiratory Crit. Care Med. 157, S214–218; discussion S218–S219, S247–S248 (1998).
Wang, Y., Armando, A. M., Quehenberger, O., Yan, C. & Dennis, E. A. Comprehensive ultra-performance liquid chromatographic separation and mass spectrometric analysis of eicosanoid metabolites in human samples. Journal of Chromatogr. A. 1359, 60–69 (2014).
Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl Acad. Sci. USA 94, 4318–4323 (1997).
Chou, W. L. et al. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor γ activation. J. Biol. Chem. 282, 18162–18172 (2007).
Baker, P. R. et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 280, 42464–42475 (2005).
Groeger, A. L. et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6, 433–441 (2010).
Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler. Thromb. Vascular Biol. 31, 986–1000 (2011).
Passarelli, M. K., Ewing, A. G. & Winograd, N. Single-cell lipidomics: characterizing and imaging lipids on the surface of individual Aplysia californica neurons with cluster secondary ion mass spectrometry. Anal. Chem. 85, 2231–2238 (2013).
Zemski Berry, K. A., Gordon, W. C., Murphy, R. C. & Bazan, N. G. Spatial organization of lipids in the human retina and optic nerve by MALDI imaging mass spectrometry. J. Lipid Res. 55, 504–515 (2014).
Fitzgerald, D. J. & Fitzgerald, G. A. Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circul. Res. 112, 174–194 (2013).
Patrono, C. & Baigent, C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation 129, 907–916 (2014).
Serhan, C. N., Hamberg, M. & Samuelsson, B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl Acad. Sci. USA 81, 5335–5339 (1984).
Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N. & Bazan, N. G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl Acad. Sci. USA 101, 8491–8496 (2004).
Marcheselli, V. L. et al. Novel docosanoids inhibit brain ischemia–reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807–43817 (2003).
Dalli, J., Chiang, N. & Serhan, C. N. Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc. Natl Acad. Sci. USA 111, E4753–E4761 (2014).
Morimoto, K. et al. Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. J. Immunol. 192, 1130–1137 (2014).
Bray, M. A., Cunningham, F. M., Ford-Hutchinson, A. W. & Smith, M. J. Leukotriene B4: a mediator of vascular permeability. Br. J. Pharmacol. 72, 483–486 (1981).
Minami, T. et al. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br. J. Pharmacol. 133, 438–444 (2001).
Lin, C. R. et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J. Pharmacol. Exp. Ther. 319, 1096–1103 (2006).
Moriyama, T. et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol. Pain 1, 3 (2005).
Lazarus, M. et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat. Neurosci. 10, 1131–1133 (2007).
Treffkorn, L., Scheibe, R., Maruyama, T. & Dieter, P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat. 74, 113–123 (2004).
Jakobsson, P. J., Thoren, S., Morgenstern, R. & Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl Acad. Sci. USA 96, 7220–7225 (1999).
Cheng, K. et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA 103, 6682–6687 (2006).
Liang, X., Wu, L., Hand, T. & Andreasson, K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J. Neurochem. 92, 477–486 (2005).
Taketomi, Y. et al. Mast cell maturation is driven via a group III phospholipase A2–prostaglandin D2–DP1 receptor paracrine axis. Nat. Immunol. 14, 554–563 (2013).
Spik, I. et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J. Immunol. 174, 3703–3708 (2005).
Schratl, P. et al. The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking. J. Immunol. 179, 4792–4799 (2007).
Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813–819 (1995).
Forman, B. M. et al. 15-Deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).
Basu, S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2α from physiology to new principles in inflammation. Med. Res. Rev. 27, 435–468 (2007).
Woodward, D. F. et al. Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation. Investigative Ophthalmol. Visual Sci. 30, 1838–1842 (1989).
Moncada, S., Herman, A. G., Higgs, E. A. & Vane, J. R. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb. Res. 11, 323–344 (1977).
Murata, T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678–682 (1997).
Weiss, H. J. & Turitto, V. T. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 53, 244–250 (1979).
Lim, H. et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev. 13, 1561–1574 (1999).
Gupta, R. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275–13280 (2000).
Hartwig, J. H. et al. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 82, 643–653 (1995).
Auch-Schwelk, W., Katusic, Z. S. & Vanhoutte, P. M. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 15, 699–703 (1990).
Cogolludo, A., Moreno, L., Bosca, L., Tamargo, J. & Perez-Vizcaino, F. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Cζ. Circul. Res. 93, 656–663 (2003).
Kabashima, K. et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 4, 694–701 (2003).
Iizuka, Y. et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J. 24, 4678–4690 (2010).
Narala, V. R. et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist. J. Biol. Chem. 285, 22067–22074 (2010).
Devchand, P. R. et al. The PPARα–leukotriene B4 pathway to inflammation control. Nature 384, 39–43 (1996).
Moos, M. P. et al. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352–4362 (2008).
Hwang, S. W. et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl Acad. Sci. USA 97, 6155–6160 (2000).
Ng, V. Y. et al. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α. Drug Metabolism Dispos. 35, 1126–1134 (2007).
Liu, Y. et al. The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl Acad. Sci. USA 102, 16747–16752 (2005).
Inceoglu, B., Schmelzer, K. R., Morisseau, C., Jinks, S. L. & Hammock, B. D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82, 42–49 (2007).
Gregus, A. M. et al. Spinal 12-lipoxygenase-derived hepoxilin A3 contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors. Proc. Natl Acad. Sci. USA 109, 6721–6726 (2012).
Mrsny, R. J. et al. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc. Natl Acad. Sci. USA 101, 7421–7426 (2004).
Hurley, B. P., Siccardi, D., Mrsny, R. J. & McCormick, B. A. Polymorphonuclear cell transmigration induced by Pseudomonas aeruginosa requires the eicosanoid hepoxilin A3 . J. Immunol. 173, 5712–5720 (2004).
Nigam, S., Zafiriou, M. P., Deva, R., Ciccoli, R. & Roux-Van der Merwe, R. Structure, biochemistry and biology of hepoxilins: an update. FEBS J. 274, 3503–3512 (2007).
Hammond, V. J. & O'Donnell, V. B. Esterified eicosanoids: generation, characterization and function. Biochim. Biophys. Acta 1818, 2403–2412 (2012).
Brezinski, M. E. & Serhan, C. N. Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl Acad. Sci. USA 87, 6248–6252 (1990).
Rouzer, C. A. & Marnett, L. J. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J. Biol. Chem. 283, 8065–8069 (2008).
Trostchansky, A. et al. Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. J. Biol. Chem. 286, 12891–12900 (2011).
E.A.D. thanks the US National Institutes of Health (NIH) for National Institute of General Medical Sciences (NIGMS) grants RO1 GM20501-39 and the LIPID MAPS “Glue” grant U54 GM069338 for support of research and scholarly activity and T32 GM007752 for support of graduate training for P.C.N..
The authors declare no competing financial interests.
Enzymes in the cyclooxygenase pathway generate prostaglandins, thromboxanes, and lipoxins from arachidonic acid. (PDF 174 kb)
Enzymes in the lipoxygenase pathway generate leukotrienes, HETEs, and hepoxilins from arachidonic acid. (PDF 182 kb)
Enzymes in the cytochrome P450 epoxyhydrolase pathway generate epoxides and dihydroxy polyunsaturated fatty acids (PUFAs) from arachidonic acid. (PDF 142 kb)
Bioactive oxygenated polyunsaturated fatty acids containing 20 carbons.
- Non-steroidal anti-inflammatory drugs
(NSAIDs). Drugs, such as aspirin and naproxen, that are used to ablate the inflammatory response. They work by inhibiting cyclooxygenase 1 (COX1) and COX2, thereby blocking the biosynthesis of prostaglandins including thromboxane.
Bioactive oxygenated polyunsaturated fatty acids containing 22 carbons.
A molecular complex of several proteins that, upon assembly, cleaves pro-interleukin-1β (pro-IL-1β) and pro-IL-18, thereby producing the active forms of these pro-inflammatory cytokines.
- Toll-like receptor
(TLR). A pattern recognition receptor that recognizes conserved molecules from pathogens, such as lipopolysaccharide, and initiates innate immune responses.
- Peroxisome proliferator-activated receptor-α
(PPARα). Member of a family of nuclear receptors that participate in the regulation of cellular metabolism and differentiation. PPARs have anti-inflammatory properties as they regulate the availability of limited cofactors or block promoters of pro-inflammatory genes.
- Specialized pro-resolving mediators
(SPMs). Eicosanoids and docosanoids that promote efferocytosis and also inhibit neutrophil diapedesis and pro-inflammatory cytokine expression. SPMs include lipoxins, resolvins, protectins, maresins and the newly discovered maresin conjugates in tissue regeneration (MCTR) sulfido-conjugate series.
- Caecal ligation and puncture
An experimental model of peritonitis in rodents in which the caecum is ligated and then punctured, thereby forming a small hole. This leads to leakage of intestinal bacteria into the peritoneal cavity and subsequent peritoneal infection.
(MPO). An enzyme that is most highly expressed by neutrophils, where it is stored in azurophilic granules. MPO produces hypochlorous acid from hydrogen peroxide and chloride ions during the respiratory burst in neutrophils.
- Purinergic receptors
A family of plasma membrane-bound molecules that are involved in several known cellular functions, such as vascular reactivity, apoptosis and cytokine secretion.
Lipid mediators that are induced in the resolution phase following acute inflammation. They are synthesized from the essential ω-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid.
In the context of this Review refers to complexes of multiple enzymes (bound or in close proximity) that coordinately synthesize eicosanoids and docosanoids, which is often dependent on receptor activation and cell–cell transfer of intermediates.
The study of the flux or the change in the concentration of products and/or metabolites in a biosynthetic pathway in a cell as a function of time.
A class of eicosanoids, comprising LXA4 and LXB4, that are produced by lipoxygenase-mediated metabolism of arachidonic acid. They are trihydroxytetraene-containing structures with potent biological activities in the resolution of inflammation.
- Eicosanoid class switching
A process by which pro-inflammatory eicosanoid synthesis changes to anti-inflammatory or pro-resolution eicosanoid and docosanoid synthesis.
The phagocytic clearance of apoptotic cells (from the Latin word effero, meaning to take to the grave or bury) before they undergo secondary necrosis. The process usually triggers an anti-inflammatory response.
- Necrotic cell death
A form of cell death that frequently results from toxic injury, hypoxia or stress. Necrosis involves the loss of cell integrity and release of cell contents into the interstitium. This form of cell death usually occurs together with inflammation. Depending on the context, the self-antigens that are released by necrosis could become immunogenic.
- Lyme disease
A disease caused by the bacterium Borrelia burgdorferi or other Borrelia spp. that are transmitted to humans via the bites of infected black-legged ticks. Symptoms can include skin rash, fever, fatigue, headache, muscle pain, stiff neck, and swelling of the knee and other large joints. Most cases can be successfully treated with antibiotics.
- UPLC/MS–MS technology
Ultra-high performance liquid chromatography (UPLC) combined with tandem mass spectrometry (MS–MS) for chemical separation and quantitative analysis.
About this article
Cite this article
Dennis, E., Norris, P. Eicosanoid storm in infection and inflammation. Nat Rev Immunol 15, 511–523 (2015). https://doi.org/10.1038/nri3859
Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis
Journal of Neuroinflammation (2022)
Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation
Nature Immunology (2022)
Cell Death & Disease (2022)
Nature Communications (2022)
Pediatric Research (2022)